The healthcare sector is currently navigating the transition of biometric data from consumer-grade wearable devices into formal clinical practice.

醫療健康產業目前正處於將消費級穿戴裝置的生物識別數據轉化為正式臨床實踐的過渡階段。

The proliferation of wearable technology has resulted in a substantial increase in patient-generated health metrics. However, a systemic misalignment exists between the continuous data streams produced by these devices and the episodic nature of traditional clinical care. This discrepancy is compounded by significant technical impediments regarding the interoperability of proprietary data clouds and Electronic Health Records (EHRs). Furthermore, the lack of standardized data formats and the necessity for clinicians to manage multiple disparate logins hinder the efficient synthesis of patient information.

穿戴式科技的普及，導致患者產生的健康指標大幅增加。然而，這些裝置產生的持續數據流與傳統臨床護理的片段性特質之間，存在系統性的不匹配。由於專有數據雲與電子健康紀錄（EHR）之間的互操作性存在重大技術障礙，使得這種差異更加複雜。此外，缺乏標準化的數據格式，以及臨床醫生必須管理多組不同的登入帳號，阻礙了患者資訊的高效綜合分析。

From a clinical perspective, the utility of this data is frequently undermined by a lack of transparency regarding the algorithms used to derive metrics such as 'strain' or 'recovery.' Consequently, practitioners face a professional dichotomy: the potential alienation of patients by dismissing their data, or the risk of clinical error by relying on non-validated metrics. While the Food and Drug Administration (FDA) has authorized specific features for clinical use, the broader evidence base remains nascent. To mitigate these frictions, industry actors are pursuing strategic acquisitions—such as Samsung's acquisition of Xealth—to facilitate EHR integration, while academic initiatives like JupyterHealth seek to establish open-source public infrastructure for data ingestion.

從臨床角度來看，由於推導出如「壓力」或「恢復」等指標的演算法缺乏透明度，這些數據的實用價值經常被削弱。因此，執業醫師面臨一種專業上的兩難：若否定患者的數據，可能會使患者感到被疏離；若依賴未經驗證的指標，則面臨臨床錯誤的風險。雖然美國食品藥品監督管理局（FDA）已授權特定功能用於臨床，但更廣泛的證據基礎仍處於起步階段。為了緩解這些摩擦，產業參與者正採取策略性收購——例如三星收購 Xealth——以促進 EHR 整合，而如 JupyterHealth 等學術計劃則尋求建立開源的公共基礎設施以進行數據導入。

Stakeholder positioning reflects a cautious optimism. Some clinicians acknowledge the life-saving potential of wearables in detecting irregular heart rhythms, yet emphasize that the 'digital avalanche' of information requires sophisticated filtration. The prospective implementation of Large Language Models (LLMs) is hypothesized as a potential mechanism for synthesizing this data, provided that regulatory frameworks regarding HIPAA and medical privacy are sufficiently evolved to encompass consumer devices.

利益相關者的定位反映出審慎的樂觀。部分臨床醫生承認穿戴裝置在偵測心律不整方面具有救命潛力，但強調資訊的「數位雪崩」需要精密的過濾機制。目前假設導入大型語言模型（LLM）將成為綜合分析這些數據的潛在機制，前提是關於 HIPAA 和醫療隱私的監管框架已足夠演進以涵蓋消費級裝置。

While technological and regulatory barriers persist, the movement toward integrating wearable data into clinical workflows continues through a combination of corporate integration and academic infrastructure development.

雖然技術與監管障礙依然存在，但透過企業整合與學術基礎設施發展，將穿戴數據整合至臨床工作流的趨勢仍持續推進。